⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL804646 | 0.81 | — | — | |
| Hydrochloric Acid SCHEMBL31648852 | 0.79 | HCAR2 (0.39) | — | |
| SCHEMBL24763152 | 0.77 | — | — | |
| SCHEMBL13683075 | 0.77 | — | — | |
| SCHEMBL4364411 | 0.72 | ALDH1A1 (0.35) | — | |
| SCHEMBL28653618 | 0.71 | JAK2 (0.31) | — | |
| SCHEMBL25934674 | 0.71 | CYP1A2 (0.35) | — | |
| SCHEMBL2264194 | 0.70 | HCAR2 (0.32) | — | |
| SCHEMBL20928057 | 0.68 | HCAR2 (0.38) | — | |
| SCHEMBL23531912 | 0.67 | ALPL (0.50) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114846004-B | Antimalarial drugs | 德克萨斯大学系统董事会 | 2024-10-11 | — | — | CN | disclosed |
| US-11903936-B2 | Anti-malarial agents | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2024-02-20 | — | — | US | disclosed |
| EP-4077308-B1 | ANTI-MALARIAL AGENTS | UNIV TEXAS (US) | 2024-02-14 | — | — | EP | disclosed |
| US-20230056202-A1 | ANTI-MALARIAL AGENTS | MMV MEDICINES FOR MALARIA VENTURE (CH) | 2023-02-23 | — | — | US | disclosed |
| US-20220401445-A1 | METHODS OF USING ALK2 INHIBITORS | KEROS THERAPEUTICS, INC. | 2022-12-22 | — | — | US | disclosed |
| EP-4077308-A1 | ANTI-MALARIAL AGENTS | The Board of Regents of the University of Texas System (US) | 2022-10-26 | — | — | EP | disclosed |
| CN-114846004-A | Novel antimalarial drug | 德克萨斯大学系统董事会 | 2022-08-02 | — | — | CN | disclosed |
| EP-3842100-A1 | ANTI-MALARIAL AGENTS | The Board Of Regents Of The University Of Texas System (US) | 2021-06-30 | — | — | EP | disclosed |
| WO-2021123266-A1 | ANTI-MALARIAL AGENTS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2021-06-24 | — | — | WO | disclosed |
| EP-2257160-B1 | DIAMIDE INHIBITORS OF CYTOCHROME P450 | SEQUOIA PHARMACEUTICALS INC (US) | 2017-07-05 | — | — | EP | disclosed |
| US-9540354-B2 | Diamide inhibitors of cytochrome P450 | SEQUOIA PHARMACEUTICALS, INC. (US) | 2017-01-10 | — | — | US | disclosed |
| US-20150087676-A1 | Diamide Inhibitors of Cytochrome P450 | SEQUOIA PHARMACEUTICALS INC (US) | 2015-03-26 | — | — | US | disclosed |
| US-8906647-B2 | Diamide inhibitors of cytochrome P450 | SEQUOIA PHARMACEUTICALS, INC. (US) | 2014-12-09 | — | — | US | disclosed |
| US-20110098236-A1 | DIAMIDE INHIBITORS OF CYTOCHROME P450 | SEQUOIA PHARMACEUTICALS, INC. (US) | 2011-04-28 | — | — | US | disclosed |
| EP-2257160-A1 | DIAMIDE INHIBITORS OF CYTOCHROME P450 | Sequoia Pharmaceuticals, Inc. (US) | 2010-12-08 | — | — | EP | disclosed |
| WO-2009105776-A1 | DIAMIDE INHIBITORS OF CYTOCHROME P450 | SEQUOIA PHARMACEUTICALS, INC. (US) | 2009-08-27 | — | — | WO | disclosed |